Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Maria Rosaria Anna Muscatello, Antonio Bruno, Paolo Micali Bellinghieri, Gianluca Pandolfo & Rocco Antonio Zoccali. (2014) Sertindole in schizophrenia: efficacy and safety issues. Expert Opinion on Pharmacotherapy 15:13, pages 1943-1953.
Read now
Read now
Evangelos Karamatskos, Martin Lambert, Christoph Mulert & Dieter Naber. (2012) Drug safety and efficacy evaluation of sertindole for schizophrenia. Expert Opinion on Drug Safety 11:6, pages 1047-1062.
Read now
Read now
Stephanie L Cincotta & Joshua S Rodefer. (2010) Emerging role of sertindole in the management of schizophrenia. Neuropsychiatric Disease and Treatment 6, pages 429-441.
Read now
Read now
Jean-Michel Azorin, Arthur Kaladjian, Eric Fakra & Marc Adida. (2010) Sertindole for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 11:18, pages 3053-3064.
Read now
Read now
Maria Rosaria A Muscatello, Antonio Bruno, Gianluca Pandolfo, Umberto Micò, Salvatore Settineri & Rocco Zoccali. (2010) Emerging treatments in the management of schizophrenia – focus on sertindole. Drug Design, Development and Therapy 4, pages 187-201.
Read now
Read now
Eva Lindström & Sten Levander. (2006) Sertindole: efficacy and safety in schizophrenia. Expert Opinion on Pharmacotherapy 7:13, pages 1825-1834.
Read now
Read now
Articles from other publishers (11)
Jianlin Han, Loránd Kiss, Haibo Mei, Attila Márió Remete, Maja Ponikvar-Svet, Daniel Mark Sedgwick, Raquel Roman, Santos Fustero, Hiroki Moriwaki & Vadim A. Soloshonok. (2021) Chemical Aspects of Human and Environmental Overload with Fluorine. Chemical Reviews 121:8, pages 4678-4742.
Crossref
Crossref
Rocco A. Zoccali, Antonio Bruno & Maria Rosaria Anna Muscatello. (2015) Efficacy and Safety of Sertindole in Schizophrenia. Journal of Clinical Psychopharmacology 35:3, pages 286-295.
Crossref
Crossref
Mario F. JuruenaEduardo Ponde00C9; De SenaIrismar Reis De Oliveira. (2011) Sertindole in the Management of Schizophrenia. Journal of Central Nervous System Disease 3, pages JCNSD.S5729.
Crossref
Crossref
Gregor J. Macdonald & José Manuel Bartolomé. 2010.
37
80
.
Christophe Lançon, Mondher Toumi, Christophe Sapin & Karina Hansen. (2008) The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe. BMC Psychiatry 8:1.
Crossref
Crossref
Siegfried Kasper. (2008) Do we need another atypical antipsychotic?. European Neuropsychopharmacology 18, pages S146-S152.
Crossref
Crossref
Joseph Peuskens, Per Tanghøj & Aurélia Mittoux. (2008) The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiology and Drug Safety 17:5, pages 425-433.
Crossref
Crossref
Jean-Michel Azorin, Nathalie Strub & Henrik Loft. (2006) A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. International Clinical Psychopharmacology 21:1, pages 49-56.
Crossref
Crossref
Lowijs N.M. Perquin. (2005) Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. International Clinical Psychopharmacology 20:6, pages 335-338.
Crossref
Crossref
Henrik Lublin, Jonas Eberhard & Sten Levander. (2005) Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. International Clinical Psychopharmacology 20:4, pages 183-198.
Crossref
Crossref
. (2003) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 12:6, pages 523-538.
Crossref
Crossref